Michael A Liss1, Jianfeng Xu2,3, Haitao Chen3, A Karim Kader4. 1. Department of Urology, University of Texas Health Science Center San Antonio, San Antonio, Texas. 2. State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China. 3. Departments of Genomics and Personalized Medicine Research, Wake Forest University School of Medicine, Winston-Salem, North Carolina. 4. Department of Urology, UC San Diego Health System, San Diego, California.
Abstract
BACKGROUND: To investigate the ability of the prostate genetic score (PGS-33), a germ-line biomarker of prostate cancer (PCa) risk, to categorize men participating in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. METHODS: We obtained the genetic data from the Cancer Genetic Markers of Susceptibility (CGEMS), a nested case control study examining germ-line DNA in the screened arm of the PLCO trial. A PGS-33 was calculated based on their genotype at 33 PCa associated single nucleotide polymorphisms (SNPs). The primary outcome was the diagnosis of PCa and primary predictor was PGS-33. RESULTS: We identified 2,244 subjects (no cancer, N = 1017) and cases (N = 1227). The PGS-33 (P<0.001), prostate specific antigen (PSA; P < 0.001), family history of PCa (< 0.001), abnormal digital rectal exam (DRE, P < 0.001), and history of ever smoking (P = 0.037) were associated with a PCa diagnosis. In multivariable analysis, the log (PGS-33) was associated with PCa diagnosis with an odds ratio of 1.68 (95% CI 1.36-2.08, P < 0.001), log (PSA) (OR 8.2; 95% CI 6.75-10.04, P < 0.001), and family history of PCa (OR 2.01; 95% CI 1.26-3.20, P = 0.003). PGS-33 quartiles noted an increasing rate of PCa detection in addition to PSA: 43.2% (Q1), 47.8% (Q2), 58.8% (Q3), and 69.4 (Q4) (P < 0.001) and improvement in PSA performance (P < 0.001). CONCLUSIONS: Germ-line DNA in the form of the PGS-33 is able to risk stratify men regarding their risk of PCa. The PGS-33 may have implications regarding who may benefit most from PCa screening and possibly add to PSA performance.
RCT Entities:
BACKGROUND: To investigate the ability of the prostate genetic score (PGS-33), a germ-line biomarker of prostate cancer (PCa) risk, to categorize men participating in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. METHODS: We obtained the genetic data from the Cancer Genetic Markers of Susceptibility (CGEMS), a nested case control study examining germ-line DNA in the screened arm of the PLCO trial. A PGS-33 was calculated based on their genotype at 33 PCa associated single nucleotide polymorphisms (SNPs). The primary outcome was the diagnosis of PCa and primary predictor was PGS-33. RESULTS: We identified 2,244 subjects (no cancer, N = 1017) and cases (N = 1227). The PGS-33 (P<0.001), prostate specific antigen (PSA; P < 0.001), family history of PCa (< 0.001), abnormal digital rectal exam (DRE, P < 0.001), and history of ever smoking (P = 0.037) were associated with a PCa diagnosis. In multivariable analysis, the log (PGS-33) was associated with PCa diagnosis with an odds ratio of 1.68 (95% CI 1.36-2.08, P < 0.001), log (PSA) (OR 8.2; 95% CI 6.75-10.04, P < 0.001), and family history of PCa (OR 2.01; 95% CI 1.26-3.20, P = 0.003). PGS-33 quartiles noted an increasing rate of PCa detection in addition to PSA: 43.2% (Q1), 47.8% (Q2), 58.8% (Q3), and 69.4 (Q4) (P < 0.001) and improvement in PSA performance (P < 0.001). CONCLUSIONS: Germ-line DNA in the form of the PGS-33 is able to risk stratify men regarding their risk of PCa. The PGS-33 may have implications regarding who may benefit most from PCa screening and possibly add to PSA performance.
Authors: Nathaniel Hendrix; Roman Gulati; Boshen Jiao; A Karim Kader; Stephen T Ryan; Ruth Etzioni Journal: Am J Epidemiol Date: 2021-10-01 Impact factor: 4.897
Authors: Carly A Conran; Rong Na; Haitao Chen; Deke Jiang; Xiaoling Lin; S Lilly Zheng; Charles B Brendler; Jianfeng Xu Journal: Asian J Androl Date: 2016 Jul-Aug Impact factor: 3.285
Authors: Julia Oto; Álvaro Fernández-Pardo; Montserrat Royo; David Hervás; Laura Martos; César D Vera-Donoso; Manuel Martínez; Mary J Heeb; Francisco España; Pilar Medina; Silvia Navarro Journal: Sci Rep Date: 2020-02-12 Impact factor: 4.379
Authors: Sarah Benafif; Holly Ni Raghallaigh; Eva McGrowder; Edward J Saunders; Mark N Brook; Sibel Saya; Reshma Rageevakumar; Sarah Wakerell; Denzil James; Anthony Chamberlain; Natalie Taylor; Matthew Hogben; Barbara Benton; Lucia D'Mello; Kathryn Myhill; Christos Mikropoulos; Hywel Bowen-Perkins; Imran Rafi; Michelle Ferris; Andre Beattie; Shophia Kuganolipava; Tamsin Sevenoaks; Juliet Bower; Pardeep Kumar; Steven Hazell; Nandita M deSouza; Antonis Antoniou; Elizabeth Bancroft; Zsofia Kote-Jarai; Rosalind Eeles Journal: BJU Int Date: 2021-08-15 Impact factor: 5.969